Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs APVO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APVO Captures Overall Composite Edge (45.4 HOLD vs 40.1 SELL), While MYO Leads 3–2 on Growth & Valuation Pillars

APVO Overall Winner 6-Pillar Tally: MYO 3 – 2 APVO (1 Tie) Matrix Metrics: MYO 5 – 5 APVO

As of Nov 20, 2026, Aptevo Therapeutics Inc (APVO) captures the overall head-to-head institutional edge over Myomo Inc. (MYO) on higher Unified Composite conviction (45.4/100 HOLD vs. 40.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Profitability & Quality), while MYO wins 3–2 across the 6-pillar growth and valuation breakdown. MYO trades at $0.81 (N/M Forward P/E, -21.8% operating margin) versus APVO at $0.40 (3.9x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: APVO earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. MYO 40.1/100 SELL) and 0.45β · 121% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile APVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 8.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs APVO
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
APVO NASDAQ Head-to-Head Winner
Aptevo Therapeutics Inc
Pharmaceutical Preparations
$0.40
-2.37% 1D
Market Cap $1.4M
TTM Revenue N/A
Forward P/E 3.9x
Beta / 30D Vol 0.45β · 121% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 45.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.2%), weak momentum, RSI 9
RSI-14: 8.9 · SMA20: $0.99 · SMA50: $1.46

6-Pillar Scorecard Institutional Category Breakdown (MYO 3 – 2 APVO)

Columns: Metric · MYO · APVO
1. Valuation Multiples APVO
Forward P/E N/M 3.9x
Trailing P/E N/M 0.0x
PEG Ratio N/M N/M
EV / Revenue 0.9x N/M
2. Growth & Scale MYO
Revenue Growth (YoY) +22.2% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $46M N/A
Market Cap $33.7M $1.4M
3. Profitability & Quality APVO
Gross Margin 70.1% N/A
Operating Margin -21.8% 0.0%
Net Profit Margin -33.1% 0.0%
Return on Equity (ROE) -173.5% -420.3%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$9.1M N/A
Cash Flow Margin -20.0% N/A
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $17.42 Book/Sh · -420.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 266.0% (81st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (5) vs APVO (5)
Institutional Metric MYO APVO Criterion Row Edge
Market Capitalization
Scale
$33.7M $1.4M Larger Scale MYO
Trailing P/E Ratio
Valuation
N/M 0.0x Lower Multiple APVO
Forward P/E Ratio
Valuation
N/M 3.9x Lower Multiple APVO
Revenue Growth (YoY)
Growth
+22.2% -100.0% Higher Growth MYO
Operating Margin (TTM)
Profitability
-21.8% 0.0% Higher Margin APVO
Net Profit Margin
Profitability
-33.1% 0.0% Higher Margin APVO
Return on Equity (ROE)
Capital Efficiency
-173.5% -420.3% Higher ROE MYO
52-Week Range Position
Momentum
16% ($1–$2) 0% ($0–$11) Stronger Trend MYO
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 0.45β · 121% Vol Lower Realized Risk MYO
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 45.4 / 100 (HOLD) Higher Composite APVO
Trailing 12M Revenue (USD)
Operating Scale
$46M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) N/A ($17.42 Book/Sh · -420.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYO +41.38 pp
MYO: -33.52% · APVO: -74.9%
3M Horizon MYO +41.58 pp
MYO: -41.65% · APVO: -83.23%
6M Horizon MYO +69.82 pp
MYO: -22.02% · APVO: -91.84%
1Y Horizon MYO +79.18 pp
MYO: +12.3% · APVO: -66.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYO Revenue APVO Revenue MYO Op. Margin APVO Op. Margin Margin Leader
FY2018 $0M $20M -430.8% -224.0% APVO
FY2019 $0M $30M -281.3% -126.3% APVO
FY2020 $10M $0M -138.5% -638.1% MYO
FY2021 $10M $10M -74.1% -174.1% MYO
FY2022 $20M $0M -68.6% -919.7% MYO
FY2023 $20M N/A -42.8% N/A MYO
FY2024 $30M N/A -19.1% N/A MYO
FY2025 $40M N/A -35.2% N/A MYO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APVO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact APVO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
APVO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs APVO Key Questions & Quantitative Answers

As of Nov 20, 2026, Aptevo Therapeutics Inc (APVO) captures the overall head-to-head institutional edge over Myomo Inc. (MYO) on higher Unified Composite conviction (45.4/100 HOLD vs. 40.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Profitability & Quality), while MYO wins 3–2 across the 6-pillar growth and valuation breakdown. MYO trades at $0.81 (N/M Forward P/E, -21.8% operating margin) versus APVO at $0.40 (3.9x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: APVO earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. MYO 40.1/100 SELL) and 0.45β · 121% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile APVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 8.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYO leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with APVO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while APVO shifted -50.0%. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for APVO.

APVO screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas APVO trades at 3.9x Forward P/E, 0.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus APVO (-420.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, APVO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.